Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level

Wona Choi1,2, Yoon-Sik Yang2, Dong-Jin Chang3, Yeon Woong Chung1,4, HyungMin Kim1,2, Soo Jeong Ko1,2, Sooyoung Yoo5, Ji Seon Oh6, Dong Yoon Kang7, Hyeon-Jong Yang8 & In Young Choi*

Allopurinol is the first-line agent for patients with gout, including those with moderate-to-severe chronic kidney disease. However, increased thyroid-stimulating hormone (TSH) levels are observed in patients with long-term allopurinol treatment. This large-scale, nested case–control, retrospective observational study analysed the association between allopurinol use and increased TSH levels. A common data model based on an electronic medical record database of 19,200,973 patients from seven hospitals between January 1997 and September 2020 was used. Individuals aged > 19 years in South Korea with at least one record of a blood TSH test were included. Data of 59,307 cases with TSH levels > 4.5 mIU/L and 236,508 controls matched for sex, age (± 5), and cohort registration date (± 30 days) were analysed. An association between the risk of increased TSH and allopurinol use in participants from five hospitals was observed. A meta-analysis (I² = 0) showed that the OR was 1.51 (95% confidence interval: 1.32–1.72) in both the fixed and random effects models. The allopurinol intake group demonstrated that increased TSH did not significantly affect free thyroxine and thyroxine levels. After the index date, some diseases were likely to occur in patients with subclinical hypothyroidism and hypothyroidism. Allopurinol administration may induce subclinical hypothyroidism.

Gout is the most common form of inflammatory arthritis, caused by chronic elevation in serum uric acid levels above the saturation point of monosodium urate. This leads to the deposition of monosodium urate crystals in the joints, tendons, and other tissues, triggering recurrent episodes of pronounced acute inflammation known as gout flares.

In recent decades, gout incidence has increased in many countries. Although its prevalence in South Korea is lower than that in other countries, the incidence increased by 25% between 2009 and 2015, according to a study using the national health insurance claim database. Dietary factors, increasing age, and comorbid conditions were environmental influences on gout incidence.

As the primary urate-lowering therapy, xanthine oxidase inhibitors (XOIs) such as allopurinol (the preferred first-line agent) or febuxostat are strongly recommended for all patients, including those with moderate-to-severe chronic kidney disease (CKD). According to previous studies, XOIs increase blood thyrotropin (TSH) levels. Increased TSH levels (> 5.5 μIU/mL) were observed in patients on long-term treatment with allopurinol (5.8%) in a long-term, open-label extension study. In a study by Perez-Ruiz et al., 88 patients receiving febuxostat and 87 patients receiving allopurinol were followed up for 12 months to measure changes in TSH levels. The authors found significant increases in TSH levels (> 5.5 μIU/mL) in 3.4% of patients using allopurinol and 7.9% of patients using febuxostat. Increased TSH levels were not associated with changes in free thyroxine (FT4) levels.

Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2Department of Biomedicine and Health Sciences, The Catholic University of Korea, Seoul, Republic of Korea. 3Department of Ophthalmology, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea. 4Department of Ophthalmology and Visual Science, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 5Healthcare ICT Research Centre, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 6Department of Information Medicine, Big Data Research Centre, Asan Medical Centre, Seoul, Republic of Korea. 7Drug Safety Monitoring Centre, Seoul National University Hospital, Seoul, Republic of Korea. 8Department of Pediatrics, Soonchunhyang University College of Medicine, Asan, Republic of Korea. *email: iychoi@catholic.ac.kr
In 2017, the European Medicines Agency recommended that product information of allopurinol should be updated to include information regarding increased TSH levels in patients undergoing long-term treatment\(^\text{10}\). Information on increases in TSH appears on medication labels in Europe, including in the United Kingdom, France, Germany, Switzerland, and Italy\(^\text{11-15}\). In Korea, the label of allopurinol was updated to include this information in April 2020\(^\text{16}\). Despite the update on medication labels of allopurinol, there is no known evidence that allopurinol use is related to increased TSH levels in Korea.

Observational databases have different logical organisations and physical formats, and terminologies used to describe medicinal products and clinical conditions vary across sources\(^\text{17}\). A common data model (CDM) could be used to create a standardised data structure to utilise hospital data efficiently to overcome these difficulties. The CDM is a distributed database system of encrypted and de-identified information that identifies patients and converts their information to secondary data sources in a common format. Medical records are converted into standardised data in a common format and used as secondary data sources through the distributed research network.

This CDM allows for a range of standard queries and analytic methods developed centrally to be run seamlessly in both the distributed and centralised environments, potentially leading to rapid quality-assured results\(^\text{18}\). The MOA CDM from the Korea Institute of Drug Safety and Risk Management includes the Sentinel CDM from the US Food and Drug Administration and the Observational Medical Outcomes Partnership (OMOP) CDM from Observational Health Data Sciences and Informatics (OHDSI)\(^\text{19}\). The OMOP CDM is the most widely used model, developed and managed by the OHDSI in Korea.

In this retrospective, observational study targeting a large cohort of Korean population groups in multiple centres, we performed an analysis of the association between allopurinol and increased TSH levels using the OMOP CDM.

**Methods**

**Data source and study design.** This was a nested case–control study using distributed OMOP CDM databases loaded with data records from 19,200,973 patients based on electronic medical records (EMR) from seven hospitals. These data included demographic information, medical diagnoses, prescriptions, referrals, laboratory test results, and clinical values.

The Research Ethics Committee of the seven university hospitals (Seoul St. Mary’s Hospital, Seoul Asan Hospital, St. Vincent’s Hospital, Yeouido St. Mary’s Hospital, Soonchunhyang University Hospital Seoul, Seoul National University Bundang Hospital, and Seoul National University Hospital) approved the study. This study used CDM data, which were de-identified, and involved no more than minimal risk to subjects. The requirement for written informed consent was waived by the Research Ethics Committee of the Catholic Medical Centre and this study was in accordance with relevant guidelines and regulations.

**Selection of cases and controls.** This cohort included patients aged 19 years or older with at least one record of blood TSH test registered between 1 January 1997 and 18 September 2020. The date of registration was that of the first TSH test. Those who met any exclusion criteria during the entire period from the start date of the observation period to 1 year after the registration date were excluded. We excluded patients with TSH levels < 0.5 mIU/L or > 4.5 mIU/L; those diagnosed with thyroid diseases, Graves’ disease, pituitary tumour, pituitary gland dysfunction resulting in Sheehan’s syndrome, and those who underwent thyroidectomy. Patients receiving antithyroid medications, levothyroxine, thyroid supplements, or radioiodine therapy were also excluded (Supplementary Table S1). Case and control patients were selected 1 year after the date of registration (Fig. 1).

To reduce bias, we collected and reviewed the source values and standard codes of each hospital in advance and selected 5 out of 108 items for TSH. We confirmed that all seven hospitals participating in the study received laboratory accreditation from the Laboratory Medicine Foundation ensure the reliability of test result. Besides, we collected the normal range for TSH from the seven hospitals participating in the study. Then, we combined and compared the values in previous studies, and decided the cut off value TSH as 0.5 to 4.5 mIU/L with the help of an endocrinology specialist.

Patients whose TSH levels were > 4.5 mIU/L after 1 year of cohort registration were allocated to the case group, and those having levels > 4.5 mIU/L at the date of the first test were assigned to the index date of the case group. The patients in the control group who had TSH levels from 0.5 to 4.5 mIU/L were matched four times...
with the case group for sex, age (± 5), and date of cohort registration (± 30 days) using incidence density sampling without replacement. The control index date was assigned as the case group index date of the patients matching.

**Exposure.** Details of medication prescriptions, including allopurinol were obtained (Supplementary Table S2). We selected the look-back period of allopurinol use for 6 months before the case–control index date and determined whether allopurinol was prescribed.

**Confounding variables.** Confounding variables were selected by reviewing previous studies and expert consultations based on data available on the CDM network. We considered diseases and medications that could affect TSH levels as confounding variables and analysed the records for 6 months before selecting the case and control groups.

Diseases included 17 disease groups (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, hemiplegia or paraplegia, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, diabetes without chronic complications, diabetes with chronic complications, renal disease, any malignancy including leukaemia and lymphoma, metastatic solid tumour, mild liver disease, moderate or severe liver disease, and acquired immune deficiency syndrome/human immunodeficiency virus (AIDS/HIV) of the Charlson Comorbidity Index (CCI)20–22 and pituitary disease24,25. Medications included those that could affect TSH levels26–34 and medication used by gout patients, such as non-steroidal anti-inflammatorys, acetaminophen, oxycodone, colchicine, and corticosteroids35,36 (Supplementary Table S3).

**Statistical analyses.** Each hospital’s database was converted to the OMOP CDM version 5 format using the same table structures and standardised data. The association between allopurinol use and increment in TSH levels was analysed using a standardised analytical code. We used conditional logistic regression37 to estimate the adjusted odds ratio (OR) that increased TSH levels because of allopurinol exposure for the confounding variables. The overall effects were evaluated using a meta-analysis method, a statistical analysis combining the results of each hospital and a forest plot. Statistical approaches (I² value test) were used to test for heterogeneity. We performed the following additional analyses for the case group that was prescribed allopurinol: (1) changes in TSH levels; (2) changes in FT4 and thyroxine (T4) levels; and (3) diseases diagnosed after the index date of the case group (the first increase in TSH). All analyses were performed using R 4.0.2 (http://www.R-project.org), and two-sided p-values lower than 0.05 were considered statistically significant.

**Results**

**Clinical characteristics.** The total population of all CDM databases was 19,200,973 patients from seven hospitals. A total of 2,298,492 patients were registered in the cohort according to the inclusion criteria, and 605,420 patients were excluded. Finally, the cohort comprised 1,693,072 patients.

The case group had 59,307 case patients (TSH > 4.5 mIU/L) who were matched with 236,508 control patients for sex, age (± 5), and the date of cohort registration (± 30 days) using incidence density sampling without replacement after 1 year from the date of cohort registration. Detailed information regarding the number of cases and controls is described in Fig. 2.

Table 1 presents the clinical characteristics of the study population. All medications that were considered confounding variables showed significant differences between the case and control groups. Therefore, cases were found to more likely use the medication than controls. Among the diseases considered confounding variables, all diseases showed significant differences between the case and control groups. The case group had a higher incidence of disease than the control group.

**Association between allopurinol use and increased TSH.** Allopurinol use was associated with an increased risk of elevated TSH in five of seven hospitals (Table 2). Figure 1 presents the adjusted OR of allopurinol use for increased TSH levels from the meta-analysis. The OR was 1.51 (95% confidence interval, 1.32–1.72) in both the fixed effects and random effects models. In the meta-analysis, the fraction of variance due to heterogeneity was estimated using the statistic I²; the I² value was zero (Fig. 3).

**Additional analysis.** We performed an additional analysis for patients who used allopurinol. The cohort end date was set as the date 1 year after the last use of allopurinol and the changes in TSH levels, TSH value at the date of cohort registration, index date of the case, maximum TSH value after the case index date, and mean TSH value after the case index date were analysed.

The mean TSH level was 2.49 mIU/L at the date of cohort registration and 10.54 mIU/L at the index date in the case group. The mean TSH level was 12.52 mIU/L. The mean TSH level between the index date and cohort end date was 7.64 mIU/L in the case group (Table 3).

We analysed the FT4 and T4 values before and after the index date of the case group. The mean FT4 level was within the normal reference range after the case group’s index date in all hospitals. The mean T4 level was within the normal reference range in all hospitals (Table 4).

We analysed new diseases that occurred after the case group’s index date based on the International Classification of Diseases 10th Revision (ICD-10) code in the case of patients who used allopurinol. CKD (N18) was the most common (in 133 cases), followed by gastro-oesophageal reflux disease (GERD) (K21) in 117, chronic ischaemic heart disease (IHD) (I25) in 113, type 2 diabetes mellitus (T2DM) (E11) in 97, and gastritis and duodenitis (K29) in 83 (Table 5).
**Discussion**

We found an association between allopurinol use and an increased TSH level using a CDM based on the EMRs of 19,200,973 patients in the distributed databases of seven hospitals. All medications and diseases considered confounding variables showed significant differences between the case and control groups. The adjusted OR for the risk between increased TSH and allopurinol use in each hospital, after an aggregated meta-analysis, was 1.51 (95% CI; 1.32–1.72). Regarding the additional analysis of patients who used allopurinol, the mean maximum TSH level was 12.52 mIU/L and the highest level was 16.92 mIU/L at hospital G. Since free T4 levels were all within the normal reference range even after the case group index date (that is, when the TSH level increased), the possibility of subclinical hypothyroidism (SCH) could be suspected.

Serum TSH measurement is the single most reliable test to diagnose all common forms of hypothyroidism and hyperthyroidism. The best way to initially test thyroid function is to measure TSH levels in a blood sample. Most laboratories report a normal TSH reference range of 0.4–0.5 mIU/L on the lower end and 4–5.5 mIU/L on the upper end of the range. Primary hypothyroidism is manifested by elevated serum TSH with low serum FT4 levels. In SCH, although FT4 levels were within the normal reference range, there were elevations in TSH.

Our findings are consistent with those of Perez-Ruiz et al. and Faisal et al. These studies showed that allopurinol use affected TSH levels and was associated with the onset of SCH. We identified diseases that occurred after the case group's index date based on the ICD-10 codes for patients who used allopurinol. They were CKD, GERD, chronic IHD, T2DM, gastritis, and duodenitis, among others. These diseases have a high prevalence in patients with SCH or hypothyroidism, as reported by previous studies. These findings accorded with those of previous studies of associations between SCH or hypothyroidism and CKD, GERD, IHD, and T2DM.

Other studies have suggested that SCH is associated with an increased risk of coronary heart disease (CHD) events. In particular, CHD mortality rates increased in those with higher TSH levels, particularly in those with...
|                      | Total    | Case patients | Controls | χ²   | p value |
|----------------------|----------|---------------|----------|------|---------|
|                      | n (%)    | n (%)         | n (%)    |      |         |
| Total                | 295,815  | 59,307 (20.05)| 236,508  | 0.510|         |
| Sex                  |          |               |          |      |         |
| Male                 | 114,732  | 23,039 (20.05)| 91,693   | 0.730|         |
| Female               | 181,083  | 36,268 (20.05)| 144,815  |      |         |
| Age (years)          |          |               |          |      |         |
| Mean (SD)            | 55.23 (13.06) | 55.63 (13.26) | 55.13 (13.00) |      |         |
| 19–29                | 7435 (2.51) | 1500 (2.53)   | 5935 (2.51) | < 0.001|         |
| 30–39                | 26,426 (8.93)| 5031 (8.48)   | 21,395 (9.05) |      |         |
| 40–49                | 65,489 (22.14)| 12,825 (21.62)| 52,664 (22.27) |      |         |
| 50–59                | 88,710 (29.99)| 17,934 (30.24)| 70,776 (29.93) |      |         |
| 60–69                | 63,352 (21.42)| 12,537 (21.14)| 50,815 (21.49) |      |         |
| 70–79                | 34,569 (11.69)| 7119 (12.00)  | 27,450 (11.61) |      |         |
| ≥ 80                 | 9834 (3.32) | 2361 (3.98)   | 7473 (3.16)  |      |         |
| Medication           |          |               |          |      |         |
| Tyrosine kinase inhibitors | 382 (0.13) | 227 (0.38)  | 155 (0.07) | < 0.001|         |
| Cancer immunotherapy | 70 (0.20)  | 62 (0.10)    | 8 (0.00)  | < 0.001|         |
| Anti-tuberculosis medications | 462 (0.16) | 204 (0.34) | 258 (0.11) | < 0.001|         |
| Dobutamine           | 287 (0.10) | 197 (0.33)   | 90 (0.04)  | < 0.001|         |
| Octreotide           | 42 (0.01)  | 18 (0.03)    | 24 (0.01)  | < 0.001|         |
| Interferon-α         | 133 (0.04) | 111 (0.19)   | 22 (0.01)  | < 0.001|         |
| Amiodarone           | 1613 (0.55)| 1282 (2.16)  | 331 (0.14) | < 0.001|         |
| Azathioprine         | 380 (0.13) | 135 (0.23)   | 245 (0.10) | < 0.001|         |
| Mercaptopurine       | 17 (0.01)  | 7 (0.01)     | 10 (0.00)  | 0.029 |         |
| Warfarin             | 3015 (1.02)| 1313 (2.21)  | 1702 (0.72) | < 0.001|         |
| Dopamine             | 444 (0.15) | 271 (0.46)   | 173 (0.07) | < 0.001|         |
| Metformin            | 11,099 (3.75)| 4016 (6.77) | 7083 (2.99) | < 0.001|         |
| NSAIDs               | 28,054 (9.48)| 10,867 (18.32)| 17,187 (7.27) | < 0.001|         |
| Acetaminophen        | 10,961 (3.71)| 5235 (8.83) | 5726 (2.42) | < 0.001|         |
| Oxycodone            | 1346 (0.46)| 642 (1.08)   | 704 (0.30) | < 0.001|         |
| Colchicine           | 438 (0.15) | 166 (0.28)   | 272 (0.12) | < 0.001|         |
| Corticosteroid       | 10,474 (3.54)| 4437 (7.48) | 6037 (2.55) | < 0.001|         |
| Disease              |          |               |          |      |         |
| Panhypopituitarism   | 42 (0.01)  | 25 (0.04)    | 17 (0.01)  | < 0.001|         |
| Myocardial Infarction| 1362 (0.46)| 480 (0.81)   | 882 (0.37) | < 0.001|         |
| Congestive heart failure | 2390 (0.81)| 1221 (2.06) | 1169 (0.49) | < 0.001|         |
| Peripheral vascular disease | 1497 (0.51)| 561 (0.95) | 936 (0.40) | < 0.001|         |
| Cerebrovascular disease | 5514 (1.86)| 1793 (3.02) | 3721 (1.57) | < 0.001|         |
| Dementia             | 2440 (0.82)| 632 (1.07)   | 1808 (0.76) | < 0.001|         |
| Chronic pulmonary disease | 3021 (1.02)| 1180 (1.99) | 1841 (0.78) | < 0.001|         |
| Rheumatologic disease | 1710 (0.58)| 597 (1.01) | 1113 (0.47) | < 0.001|         |
| Peptic ulcer disease | 3134 (1.06)| 1140 (1.92) | 1994 (0.84) | < 0.001|         |
| Mild liver disease   | 2840 (0.96)| 1115 (1.88) | 1725 (0.73) | < 0.001|         |
| Diabetes without chronic complications | 12,413 (4.20)| 4905 (8.27) | 7508 (3.17) | < 0.001|         |
| Diabetes with chronic complications | 7832 (2.65)| 3199 (5.39) | 4633 (1.96) | < 0.001|         |
| Hemiplegia or paraplegia | 292 (0.10) | 147 (0.25) | 145 (0.06) | < 0.001|         |
| Renal disease        | 3637 (1.23)| 1834 (3.09) | 1803 (0.76) | < 0.001|         |
| Any malignancy       | 13,631 (4.61)| 6912 (11.65)| 6719 (2.84) | < 0.001|         |
| Moderate or severe liver disease | 225 (0.08)| 124 (0.21) | 101 (0.04) | < 0.001|         |
| Metastatic solid tumour | 1726 (0.58)| 1259 (2.12) | 467 (0.20) | < 0.001|         |
| AIDS/HIV             | 67 (0.02)  | 25 (0.04)    | 42 (0.02)  | < 0.001|         |
| CCI group            |          |               |          |      |         |
| Continued            |          |               |          |      |         |
### Table 1. Characteristics of the study population. SD Standard deviation, NSAIDs Nonsteroidal anti-inflammatory drugs, AIDS/HIV Acquired immune deficiency syndrome/human immunodeficiency virus, CCI Charlson comorbidity index.

| Total | Case patients | Controls | χ² |
|-------|---------------|----------|----|
|       | n (% )  | n (%)  | n (%)  | p value |
| 0  | 264,455  (89.4) | 45,957  (77.49) | 218,498  (92.39) | <0.001 |
| 1  | 8634  (2.92) | 3010  (5.08) | 5624  (2.38) |    |
| 2  | 15,722  (5.31) | 6658  (11.23) | 9064  (3.83) |    |
| >3  | 7004  (2.37) | 3682  (6.21) | 3322  (1.40) |    |

### Table 2. Crude and adjusted odds ratios (ORs) showing the association between allopurinol use and increased thyroid-stimulating hormone (TSH) levels. CI Confidence interval.

| Hospital | Allopurinol use | Case patients | Controls | Crude OR | Adjusted OR |
|----------|----------------|---------------|----------|----------|-------------|
|          | n = 59,307     | n = 236,508   |          |          |             |
| A        | No             | 6520  98.10   | 6520  98.10 | 99.44    | 3.40 (2.68, 4.32) | 1.41 (1.07, 1.87) |
|          | Yes            | 126  1.90     | 126  1.90 | 0.56     | 4.01 (1.86, 8.66) | 1.98 (0.79, 4.93) |
| B        | No             | 29,694 99.42 | 29,694 99.42 | 118,844 99.83 | 3.43 (2.80, 4.20) | 1.47 (1.17, 1.86) |
|          | Yes            | 174  0.58     | 174  0.58 | 0.17     | 4.63 (3.01, 7.12) | 1.71 (1.00, 2.91) |
| C        | No             | 2347 99.45 | 2347 99.45 | 9409 99.86 | 4.01 (1.98, 8.66) | 1.98 (0.79, 4.93) |
|          | Yes            | 13  0.55     | 13  0.55 | 0.14     | 4.63 (3.01, 7.12) | 1.71 (1.00, 2.91) |
| D        | No             | 1049 95.89 | 1049 95.89 | 4314 99.08 | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
|          | Yes            | 45  4.11     | 45  4.11 | 0.92     | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
| E        | No             | 3737 98.21 | 3737 98.21 | 15,030 99.66 | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
|          | Yes            | 68  1.79     | 68  1.79 | 0.34     | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
| F        | No             | 6822 99.13 | 6822 99.13 | 34,458 99.66 | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
|          | Yes            | 60  0.87     | 60  0.87 | 0.19     | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
| G        | No             | 8570 99.05 | 8570 99.05 | 34,458 99.66 | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |
|          | Yes            | 82  0.95     | 82  0.95 | 0.34     | 5.26 (3.66, 7.56) | 1.25 (0.79, 1.96) |

### Figure 3. Forest plot. OR Odds ratio, CI Confidence interval.
Our study has several limitations. This observational study showed associations, but it was unable to determine causality. Traditional medical record reviews provide detailed clinical information, whereas the database of the CDM deidentifies personal information to protect patient privacy. Additional information was not available in this study. Due to the lack of laboratory results, we could not consider the thyroid autoimmune reaction and iodine status as covariates in this study. It is important to consider these in the study design. Laboratory tests for a thyroid autoimmune reaction detect the presence and measure the number of specific thyroid autoantibodies in the blood. Therefore, if laboratory values are out of normal range in a patient who uses allopurinol, we can suspect that allopurinol causes autoimmune diseases. Although the analyses accounted for a wide range of potential confounding variables, there is potential for residual confounding and indication biases in observational studies. Also a retrospective study, it is important to standardize and confirm the laboratory items using a laboratory study because the study is related to the reliability of the inspection items and results. Therefore, a further study that reflects these considerations is required.

### Table 3. Changes in thyroid-stimulating hormone (TSH) levels. SD Standard deviation.

| Hospital | Variable | Cohort registration | Index date | Max | Mean |
|----------|----------|---------------------|------------|-----|------|
| Total    | Mean ± SD | 2.49 ± 1.06         | 10.54 ± 18.11 | 12.52 ± 19.72 | 7.64 ± 15.15 |
|          | n        | 568                 | 568        | 2021 |
| A        | Mean ± SD | 2.48 ± 1.02         | 8.1 ± 10.18 | 9.12 ± 10.7 | 5.94 ± 7.93 |
|          | n        | 126                 | 126        | 413   |
| B        | Mean ± SD | 2.31 ± 1.04         | 11.91 ± 18.5 | 15.5 ± 22.18 | 9.59 ± 17.51 |
|          | n        | 174                 | 174        | 642   |
| C        | Mean ± SD | 2.28 ± 0.87         | 6.18 ± 1.93 | 6.2 ± 1.92 | 5.53 ± 2.07 |
|          | n        | 13                  | 13         | 20    |
| D        | Mean ± SD | 2.44 ± 0.93         | 11.65 ± 22.63 | 13.25 ± 22.91 | 8.25 ± 15.61 |
|          | n        | 45                  | 45         | 170   |
| E        | Mean ± SD | 2.47 ± 1.07         | 8.87 ± 12.5 | 10 ± 12.77 | 5.73 ± 8.28 |
|          | n        | 68                  | 68         | 199   |
| F        | Mean ± SD | 2.79 ± 1.46         | 7.99 ± 12.33 | 8.63 ± 13.79 | 5.67 ± 9.69 |
|          | n        | 60                  | 60         | 250   |
| G        | Mean ± SD | 2.78 ± 1.02         | 14.69 ± 39.86 | 16.92 ± 41.06 | 8.42 ± 28.85 |
|          | n        | 82                  | 82         | 327   |

### Table 4. Changes in free thyroxine (FT4) and thyroxine (T4) levels. SD Standard deviation, FT4 Free thyroxine, T4 Thyroxine.

| Hospital | Variable | FT4 (ng/dL) | T4 (μg/dL) |
|----------|----------|-------------|------------|
|          |          | Before | After | Before | After |
|          |          | Index date | Index date | Index date | Index date |
| Total    | Mean ± SD | 1.23 ± 0.32 | 1.2 ± 0.2 | 8.03 ± 1.25 | 7.27 ± 1.23 |
|          | n        | 513     | 526     | 62      | 27     |
| A        | Mean ± SD | 1.22 ± 0.21 | 1.17 ± 0.24 | 8.75 ± 2.41 | 6.82 ± 1.98 |
|          | n        | 112     | 117     | 19      | 9      |
| B        | Mean ± SD | 1.31 ± 0.57 | 1.3 ± 0.26 | 8.12 ± 1.87 | 6.66 ± 2.49 |
|          | n        | 163     | 167     | 29      | 13     |
| C        | Mean ± SD | 1.1 ± 0.14 | 0.9 ± 0.18 | 8.38 ± 1.76 | 10.53 |
|          | n        | 13      | 13      | 2       | 3      |
| D        | Mean ± SD | 1.15 ± 0.29 | 1.11 ± 0.28 | 5.96 ± 2.16 | 6.21 ± 0.46 |
|          | n        | 44      | 45      | 6       | 3      |
| E        | Mean ± SD | 1.23 ± 0.41 | 1.2 ± 0.27 | 7.33 ± 2.51 | 4.5    |
|          | n        | 65      | 59      | 6       | 3      |
| F        | Mean ± SD | 1.29 ± 0.3 | 1.24 ± 0.18 | 7.33 ± 2.51 | 4.5    |
|          | n        | 39      | 44      | 6       | 1      |
| G        | Mean ± SD | 1.11 ± 0.3 | 1.11 ± 0.27 | 5.96 ± 2.16 | 6.21 ± 0.46 |
|          | n        | 77      | 81      | 6       | 3      |

Reference range FT4: 0.9–1.7 ng/dL, T4: 5.0–11.0 μg/dL.
To date, the understanding of pathogenetic effects and mechanisms of allopurinol on TSH limited. An experimental study on rats revealed decreases of both triiodothyronine and thyroxine levels in thyrotoxicosis rats receiving allopurinol compared with untreated thyrotoxicosis rats, and the authors suggested an association between allopurinol and the biosynthesis of thyroid hormones. However, this theory has been not proven in clinical studies. Only a few reports suggested possible mechanisms in human studies. Faisal et al. guessed that allopurinol use might affect the enlarged thyroid gland, change echogenicity, and increase blood supply with nodule formation. On the other hand, Perez-Ruiz et al. assumed that changes in TSH might be directly associated with inhibition of xanthine oxidase because a higher dose had a greater impact on TSH in their study.

Nevertheless, we provided evidence for the safety of the medication using multicentre CDM data. Though allopurinol labels have recently changed in Korea based on previous research and approval from other countries, there has been a lack of relevant large-scale analysis to date.

SCH implies an absence of symptoms; however, it is perhaps better thought of as mild hypothyroidism. Moreover, even mild hypothyroidism can progress to overt hypothyroidism in most patients and therefore requires hormone replacement over a lifetime. Therefore, it is essential to provide evidence for the safety of the medication.

The risk of an increased TSH level was significantly higher in the allopurinol use group than in the allopurinol non-use group based on a CDM built using a large-scale hospital EMR, which is highly efficient. Additional analysis confirmed the potential for the development of SCH. TSH is a sensitive indicator, which detects changes in thyroid function. Therefore, we suggest that patients using allopurinol pay attention and observe changes in thyroid function. Thyroid function changes should be monitored because related diseases do not occur immediately. Continuous follow-up is necessary, even if no specific clinical symptoms appear immediately.

**Data availability**
The data that support the findings of this study are available from each hospital. Analyses were performed locally, and the patient-level data are not readily available to be shared. The analytic code is, however, available at: [https://github.com/WonaChoi/Allopurinol-TSH](https://github.com/WonaChoi/Allopurinol-TSH).

Received: 11 June 2021; Accepted: 15 September 2021
Published online: 13 October 2021

**References**
1. Kuo, C. F., Grainge, M. J., Zhang, W. & Doherty, M. Global epidemiology of gout: prevalence, incidence and risk factors. *Nat. Rev. Rheumatol.* **11**, 649–662 (2015).
2. Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns, and risk factors. *Nat. Rev. Rheumatol.* **16**, 380–390 (2020).
3. Kim, J. W. et al. Prevalence and incidence of gout in Korea: Data from the national health claims database 2007–2015. *Rheumatol. Int.* **37**, 1499–1506 (2017).
6. Makay, O. et al. The role of allopurinol on oxidative stress in experimental hyperthyroidism. *J. Endocrinol. Invest.* 32, 641–646 (2009).

7. Perez-Ruiz, F. et al. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. *Rheumatol. Int.* 35, 1857–1861 (2015).

8. Faisal, I. M., Merkhan, M. M. & Almukhtar, H. M. Effect of chronic allopurinol therapy on thyroid function in patients with urate stones. *J. Adv. Pharm. Educ. Res.* 10, 2–5 (2020).

9. European Medicines Agency (EMA). EPACHMP Assessment Report for Adenuric. www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000777/WC00021812.draft (2008).

10. European Medicines Agency. Allopurinol: CMDh Scientific conclusions grounds variation amendments product information timetable. www.emea.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00000095/201612_en (2017).

11. UK Medicines EMC. Allopurinol label. www.medicines.org.uk/emc/product/11195/smPC (2021).

12. Italy Torrinnimexica. Product information allopurinol. www.torrinnimexica.it/schede-farmaci/allopurinolo_doc generico_100 mg_compressa_50 cp_in_blister_pvc_pvd-c al (2020).

13. France Public Medication Database. Summary of product characteristics—ALLOPURINOL. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?spid=62764225&typeDoc=R (2019).

14. AbZ Pharma. Product information of Allopurinol in Germany. https://www.abz.de/ arbitration/detai ls/prepar ate/preparate daten/detail/zn-1014636.html (2018).

15. Swissmedic. Product information ALLOPURINOL. https://www.swissmedicinfo.ch/?Lang=EN (2017).

16. Korea Ministry of Food and Medication Safety. Allopurinol medication safety-related labeling change in Korea. https://medsp.go.kr/protocol/command?CCBAQ03/getItem?totalPages=1262&limit=10&searchYN=true&page=1&title=알록루린&bbsNo=1043 (2017).

17. Reisinger, S. J. et al. Development and evaluation of a common data model enabling active medication safety surveillance using disparate healthcare databases. *J. Am. Med. Informatics Assoc.* 17, 652–662 (2010).

18. Zhou, X. et al. An evaluation of the THIN database in the OMOP common data model for active medication safety surveillance. *Medicat. Syst. 36, 119–134 (2013).

19. Korea Institute of Drug Safety and Risk Management. MOA CDM. https://moa.drugsafe.or.kr/ (2020).

20. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic in longitudinal studies: Development. *J. Chronic Dis.* 40, 373–383 (1987).

21. Kim, K. H. Comorbidity adjustment in health insurance claim database. *Health Policy Manag.* 26, 71–78 (2016).

22. Quan, H. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am. J. Epidemiol.* 173, 676–682 (2011).

23. Thygesen, S. K., Christansen, C. F., Lash, T. L., Christensen, S. & Sorensen, H. T. Predictive value of coding of diagnoses in the Charlson comorbidity index in the Danish national registry of patients. *BMC Med. Res. Methodol.* 11, 2–7 (2011).

24. Jostel, A., Ryder, W. D. J. & Shalet, S. M. The use of thyroid function tests in the diagnosis of hypothyrotoxicism: Definition and evaluation of the TSH Index. *Clin. Endocrinol. (Oxf.)* 71, 529–534 (2009).

25. Fisher, D. A., Nelson, J. C., Carlton, E. I. & Wilcox, R. B. Maturation of human hypothalamic-pituitary-thyroid function and control. *Thyroid* 10, 229–234 (2000).

26. Hannvik, O. P. R., Larsen, P. R. & Marqusee, E. Thyroid dysfunction from antineoplastic agents. *J. Natl. Cancer Inst.* 103, 1572–1587 (2011).

27. Lee, E., Chen, P., Rao, H., Lee, J. & Burmeister, L. A. Effect of acute high dose dobutamine administration on serum thyrotrophin (TSH). *Clin. Endocrinol. (Oxf.)* 50, 487–492 (1999).

28. Tripp, M. D., Wiersinga, W. & Plomp, T. A. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. *Am J Med.* 91, 507–511 (1991).

29. Lazarus, J. H. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. *Thyroid* 8, 909–913 (1998).

30. Wang, J., Gao, J., Fan, Q., Li, H. & Di, Y. The effect of metformin on thyroid-associated serum hormone levels and physiological indexes: A meta-analysis. *Curr. Pharm. Des.* 25, 3257–3265 (2019).

31. Cooper, D. S., Kilbanski, A. & Ridgway, E. C. Dopaminergic modulation of TSH and its subunits: In vivo and in vitro studies. *Clin. Endocrinol. (Oxf.)* 18, 265–275 (1983).

32. Harris, M. D., Siegel, L. B. & Alloway, J. A. Gout and hyperuricemia. *Am. Fam. Physician.* 59, 925 (1999).

33. Eskes, S. A. & Wiersinga, W. M. Amiodarone and thyroid. *Best Pract. Res. Clin. Endocrinol. Metab.* 23, 735–751 (2009).

34. Sorbo, F., Corsello, S. M., Longo, R., Barnabei, A. & Gasparini, G. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. *Nat. Rev. Clin. Oncol.* 6, 219–228 (2009).

35. Emmerson, B. T. The management of gout. *N. Engl. J. Med.* 334, 445–451 (1996).

36. Grosser, T., Smyth, E. & Fitzgerald, G. A. Anti-inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout (McGraw-Hill Companies, 2011).

37. Kuvo, C. L., Duan, Y. & Grady, J. Unconditional or conditional logistic regression model for age-matched case-control data? *Front. Public Heal.* 6, 57 (2018).

38. Biondi, B., Cappola, A. R. & Cooper, D. S. Subclinical hypothyroidism: A review. *JAMA* 322, 153–160 (2019).

39. Cooper, D. S. & Biondi, B. Subclinical thyroid disease. *Lancet* 379, 1142–1154 (2012).

40. Ladenson, P. W. et al. American Thyroid Association guidelines for detection of thyroid dysfunction. *Arch. Intern. Med.* 160, 1573–1575 (2000).

41. American Thyroid Association. Thyroid function tests. www.thyroid.org/thyroid-function-tests/ (2019).

42. Henze, M., Brown, S. J., Hadlow, N. C. & Walsh, J. P. Rationalizing thyroid function testing: Which TSH cutoffs are optimal for testing free T4? *J Clin Endocrinol Metab* 102, 4233–4241 (2017).

43. Woodmansee, W. C. Clinical thyrotoxicology for the public determination of optimal TSH ranges for reflex free T4 testing. American Thyroid Association Clinical Thyrotoxicology for the Public. https://www.thyroid.org/patient-thyroid-information/et-for-patients/february-2018/vol-11-issue-2-p-3-4 (2018).

44. Almazroa, J. F. & Gharib, H. Hypothyroidism: Etiology, diagnosis, and management. *Med. Clin. North Am.* 96, 203–221 (2012).

45. Kim, E. O. et al. Unresolved subclinical hypothyroidism is independently associated with progression of chronic kidney disease. *Int. J. Med. Sci.* 11, 52–59 (2014).

46. den Hollander, J. G., Wulkam, R. W., Mantel, M. J. & Berghout, A. Correlation between severity of thyroid dysfunction and renal function. *Clin. Endocrinol. (Oxf.)* 62, 423–427 (2005).

47. Iqbal, M. et al. Thyroid dysfunction and kidney disease. *Ear. J. Endocrinol.* 160, 503–515 (2009).

48. Baumgartner, C. et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. *Circulation* 136, 2100–2116 (2017).

49. Akyüz, F. & Soyer, O. M. Which diseases are risk factors for developing gastroesophageal reflux disease?. *Turk. J. Gastroenterol.* 28, 544–547 (2017).
50. Hamdan, A., Jabbour, J., Dowli, A., El Dahouk, I. & Azar, S. T. Prevalence of laryngopharyngeal reflux disease in patients diagnosed with hypothyroidism. *Acta Endocrinol. (Copenh.)* 8, 239–248 (2012).
51. Imaizumi, M. et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. *J. Clin. Endocrinol. Metab.* 89, 3365–3370 (2004).
52. Floriani, C., Gencer, B., Collet, T. H. & Rodondi, N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. *Eur. Heart J.* 39, 503–507 (2018).
53. Rodondi, N. et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. *Arch. Intern. Med.* 165, 2460–2466 (2005).
54. Rodondi, N. et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* 304, 1365–1374 (2010).
55. Han, C. et al. Subclinical hypothyroidism and type 2 diabetes: A systematic review and meta-analysis. *PLoS ONE* 10, 1–22 (2015).
56. Gronich, N. et al. Hypothyroidism is a risk factor for new-onset diabetes: A cohort study. *Diabetes Care* 38, 1657–1664 (2015).
57. Gencer, B. et al. Subclinical thyroid dysfunction and the risk of heart failure events in an individual participant data analysis from 6 prospective cohorts. *Circulation* 126, 1040–1049 (2012).
58. Nanchen, D. et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. *J. Clin. Endocrinol. Metab.* 97, 852–861 (2012).
59. Choi, S. A. et al. Analysis of antiepileptic drug-related adverse reactions from the electronic health record using the common data model. *Epilepsia* 61, 610–616 (2020).
60. Vanderpump, M. P. & Tunbridge, W. M. Epidemiology and prevention of clinical and subclinical hypothyroidism. *Thyroid* 10, 839–847 (2002).
61. Zimmermann, M. B. & Boelaert, K. Iodine deficiency and thyroid disorders. *Lancet. Diabetes Endocrinol.* 4, 286–295 (2015).
62. Croker, E. E., McGrath, S. A. & Rowe, C. W. Thyroid disease using diagnostic tools effectively. *Thyroid 50*, 16–21 (2021).
63. Vanderpump, M. P. J. The epidemiology of thyroid disease. *Br. Med. Bull.* 99, 39–51 (2011).
64. Rosenthal, M. J., Hunt, W. C., Garry, P. J. & Goodwin, J. S. Thyroid failure in the elderly: Microsomal antibodies as discriminant for therapy. *JAMA* 258, 209–213 (1987).
65. Park, K. H. & Lee, E. J. Recent review on medical treatment of thyroid disease. *J. Korean Med. Assoc.* 55, 1207–1214 (2012).

**Acknowledgements**

This project was funded by a grant from the Korea Institute of Drug Safety & Risk Management in 2020. Additional funding was supported by the Technology Innovation Program (20004927, Upgrade of CDM-based Distributed BioHealth Data Platform and Development of Verification Technology) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).

**Author contributions**

W.C.: study design, manuscript draft and revision, data interpretation, Y.S.Y. and H.M.K: statistical analysis, data interpretation, D.J.C.: study design, revision manuscript and data acquisition, Y.W.C.: study design and data acquisition, S.J.K., J.S.O., D.Y.K., H.J.Y.: data acquisition and data interpretation, D.J.C.: study design, revision of the manuscript and data acquisition, Y.W.C.: study design and data acquisition, S.I.K., J.S.O., D.Y.K., H.J.Y.: data acquisition, I.Y.C.: study design, data acquisition and supervision. All authors reviewed and confirmed the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98954-1.

**Correspondence** and requests for materials should be addressed to I.Y.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021